About this trial
Skeletal muscle size, an important metabolic tissue, is governed by the balance between two opposing processes, muscle protein synthesis and muscle protein breakdown. In response to long-term resistance exercise (weightlifting), skeletal muscle growth is commonly observed and it is believed that this is due to increases in muscle protein synthesis which leads to a positive net protein balance stimulating muscle growth. Due to its links to overall metabolic health, maximising muscle growth in response to resistance exercise training has become a significant focus in recent times, with various dietary supplements proposed due to their additive effects on muscle growth with resistance training. Protein supplementation, most commonly whey protein, is the most popular dietary supplement utilised by individuals completing resistance exercise training, however, more recent research has suggested that specific components of whey protein, as well as other foodstuffs, have the potential to individually activate growth pathways within skeletal muscle.
This study will investigate whether daily supplementation with a combination of these compounds is able to produce greater muscle growth, compared to a placebo, when combined with resistance exercise training. We will also investigate whether this supplement can also produce greater increase in strength as well as studying the potential mechanisms behind any of these preferential adaptations in muscle samples which will be collected before and after the training period.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Aged 18-35 years
Body Mass Index (BMI, calculated by research team based on height and weight) between 18.5-27.4 kg.m-2
Meeting UK physical activity guidelines (150 mins moderate or 75 mins vigorous activity/week)
Not currently participating in structured progressive resistance exercise training or have regularly participated in previous 6 months
Disqualifiers
Have an allergy to ingredients of the supplement or placebo supplement (e.g., legume/bean, corn allergies)
Have used dietary supplements which are known to affect skeletal muscle recovery and exercise adaptations (e.g., creatine) within the previous month
Are a smoker/vaper or have a history of smoking/vaping in previous year
Have a respiratory condition (e.g., asthma, chronic obstructive pulmonary disease)
Trial design
Parallel
Treatments tested in this trial
Resistance Exercise Training with or without daily supplementation
Other interventionThe intervention involves undertaking 3 supervised, in person, training sessions per week for 8 weeks, which are designed to increase muscle mass and strength of all major muscle groups. Each session will involve performing 7 different exercises in the order of a seated chest press, standing overhead press, bent-over row, 45-degree leg press, knee extension, seated hamstring curl, and a seated calf press. For each exercise, participants perform 4 working sets to volitional failure with 75% 1RM with a two-minute rest period will be given between sets. Resistance exercise loads will be adjusted between sets to ensure that participants consistently reach volitional failure between 8-12 repetitions and reset during week 5 when interim 1RM tests are undertaken. Throughout this period, participant will consume their assigned supplement daily either in the morning on non-training days or within 30 mins of training on training days.
Dual Energy X-Ray Absorptiometry (DEXA) Scan
RadiationParticipant's body composition will be determined through a full body DEXA scan before and after the intervention. They will have their height and weight determined prior to this scan to confirm their BMI and to calibrate the DEXA machine. The DEXA scan involves resting supine for approximately 20 minutes whilst the machine utilises a low dose of ionising radiation to estimate the total amount of fat mass and fat-free (lean) mass. The distribution of these is also determined across different body segments. The dosage of radiation is approximately 10 micro-Sieverts (µSv), which is far lower than the 80µSv airline passengers are typically exposed to during a single transatlantic flight. Scans will be conducted in line with IRMER regulations/guidelines by an appropriately trained individual.
Muscle Sampling
Procedure/SurgeryBefore and after the 8-week training intervention, a skeletal muscle (vastus lateralis) biopsy sample will be obtained from participants. This will be completed by a trained individual, in sterile conditions and under local anaesthetic using the Bergstrom needle technique modified for suction. These will be immediately processed and stored for subsequent analysis following intervention completion by all participants.
Blood Sampling
Procedure/SurgeryBefore and after the 8 week training intervention, a single 10ml venous blood sample will be collected from participant's antecubital vein. Serum and plasma will be subsequently isolated from the sample and stored for future analysis.
Leg Extensor MVC Test
Other interventionThis uses an isokinetic dynamometer to determine the peak amount of force that the leg extensor (thigh) muscles can produce during a voluntary muscle contraction. Participants will be required to sit on a padded dynameter chair with their lower legs naturally hanging over the edge of the chair, bent at a 90-degree angle. On each attempt, participants will be asked to cross their arms over their upper body and, following a count of 3 seconds, to kick as hard and as fast as possible into the stationary shin pad for 5 seconds, with peak force recorded during each attempt. This will be completed before and after the 8 week training/supplement intervention.
1 repetition maximum tests
Other interventionParticipants will next complete 1RM strength tests for 7 different resistance exercises before, mid-way and after the intervention. Each exercise will target different areas of the body and will be performed throughout the 8-week training programme. These include a seated chest press, standing overhead press, bent-over row, 45-degree leg press, knee extension, seated hamstring curl, and seated calf press. This involves lifting progressively increasing loads for each exercise until a single repetition can no longer be completed with correct form. Attempts will be separated by a rest interval of 2 minutes.
Ultrasound VL Muscle Thickness/Cross-sectional Area Measurement
Procedure/SurgeryParticipants will have their vastus lateralis muscle thickness and cross-sectional area measured via an Ultrasound scan. They will be asked to lie still on a medical examination couch whilst a member of the research team locates the position of their greater trochanter and lateral condyle of the femur. The ultrasound probe will then be placed on this mark and repositioned vertically to identify the medial and lateral borders of the VL. The midpoint of these locations will be marked and the distance between the superficial and deep aponeuroses of the VL muscle will be measured to quantify VL muscle thickness. A wide-view image spanning the entire cross-section of the vastus lateralis will also be obtained for cross-sectional area assessment.
3-day weighed food diary
Other interventionParticipants will be asked to record a 3-day weighted food diary on weeks 1, 5 and 8 of the resistance training programme. The choice of days will be at the participants discretion but must include 2 weekdays and 1 weekend day to account for dietary variation throughout the week. On these days, they will be required to record all food and drink consumed which contains calories, including the weight/volume and branding. Food diaries will be analysed for macronutrient and caloric intake. This data will be used to determine whether participant's diets, especially protein intake, remains relatively stable throughout the interventional period. Full instructions on how to properly record a weighted food diary will be provided by the research team at the start of the training period. Depending on participant preference, diaries may be recorded physically within a provided logbook or electronically using a mobile application (MyFitnessPal). Weighing scales will be provided by the research team
Daily Supplementation with active or placebo comparator
Dietary supplementIn a double-blind manner, participants will be randomised to supplement or placebo cohorts. Assigned supplements will be consumed daily across the 8-week intervention either in the morning on non-training days or with 30 minutes of training on training days. The placebo will contain maltodextrin carbohydrate, whereas the supplement will comprise 5 active ingredients: 1) Dileucine (Peptide 185™, 2g/serving), 2) PeptiStrong®( 2.4g/serving), a trademarked hydrolysed Broad Bean (Vicia faba) protein extract, 3) Calcium β-hydroxy-β-methylbutyrate monohydrate (myHMB®, 1.5g/serving), a leucine metabolite in its calcium salt form, 4) Creatine monohydrate (5g/serving), , and 5) PepForm® creatine monohydrate (1g/serving), a trademarked creatine monohydrate product where creatine is bound to peptides derived from whey proteins. Supplements will be provided in opaque contained withs instructions to add one scoop (provided) of supplement/placebo to 300ml water.
Treatment groups
Trial outcomes
Primary outcomes
Leg Press 1RM strength
Maximal strength completed on a 45 degree incline, weight plate-loaded leg press machine (statistically powered primary outcome)
1RM strength for seated chest press, standing overhead press, bent-over row, 45-degree leg press, knee extension, seated hamstring curl, and standing calf press
Maximal Strength on all other exercises completed in training sessions throughout intervention
Leg extensor MVC
Maximal force production in a isometric knee extension movement using a dynamometer
Muscle growth/hypertrophy
Assessments of muscle growth/hypertrophy through macro- and micro-scopic assessments: * B-mode ultrasound assessments of vastus lateralis cross-sectional area and thickness * Immunofluorescence microscopy to assess fibre-type specific changes in fibre cross-sectional area
Secondary outcomes
Body Composition
Assessment of fat mass and fat-free mass derived from Dual energy X-ray Absorptiometry (DEXA) scans
Skeletal muscle autophagic flux
Autophagic flux will be assessed in skeletal muscle samples utilising an ex-vivo assay followed by immunoblotting
Lysosome and autophagy-related protein content
Assessed via immunoblotting with validated antibodies
Autophagic and anabolic signalling processes (phosphorylation events, translocation, colocalization)
Assessed via immunoblotting and/or immunofluorescence with validated antibodies
Sponsors and contacts
Click on the lead sponsor to view all of their trials.